Brook, M., Hennessy, C., Hester, J., Hammad, S., Alzhrani, A., Rombach, I., . . . Issa, F. (2024). Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation. Wolters Kluwer.
Style de citation Chicago (17e éd.)Brook, MO, et al. Late Treatment with Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation. Wolters Kluwer, 2024.
Style de citation MLA (9e éd.)Brook, MO, et al. Late Treatment with Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation. Wolters Kluwer, 2024.